Healthy
Conditions
Brief summary
This is an open-label, 2-Part, phase 1 study to evaluate drug interactions when DA-8010 is co-administered with Paroxetine or Mirabegron in healthy adult subjects
Interventions
DRUGDA-8010 5mg
\[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
DRUGParoxetine 20mg
\[Part 1\] DA-8010 5mg + Paroxetine 20mg
DRUGMirabegron 50mg
\[Part 2\] DA-8010 5mg + Mirabegron 50mg
Sponsors
Dong-A ST Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
2-part
Eligibility
Sex/Gender
ALL
Age
19 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult volunteer 19 years to 50 years * Body weight in the range of 40.0 to 90.0 kg and body mass index in the range of 18 to 28kg/m2 * The subjects personally signed and dated informed consent document after informed of all patient aspects of the study, fully understanding and determined spontaneously to participate * In the case of female volunteers, those who are not necessarily pregnant or lactating or who are in a surgical infertility condition (both tubular obstruction, hysterectomy, bilateral tubular resection, etc.) * The subjects who are judged appropriate to participate this clinical trial according to the physical examination, routine laboratory examination and questionnaire
Exclusion criteria
* Subject with serious active hepatobiliary (severe hepatic failure, etc.), renal(severe renal impairment, etc.), neurologic, immunologic, respiratory, digestive, endocrine, hematologic, cardiovascular(heart failure, Torsades de pointes, etc), urologic, psychological disease or history of such disease * Subject with gastrointestinal disease (peptic ulcer, gastritis, gastrospasm, gastroesophageal reflux disease, Crohn's disease, etc.) or history of such disease/surgery (excluding simple appendic surgery, hernia surgery, hemorrhoid surgery) * Subject Hypersensitive to any of the IP components or other drug components(Aspirin, Antibiotics, etc.) * Subject who is positive for serum test results (hepatitis B test, hepatitis C test, HIV test, syphilis test) * Subject who have history of drug/alcohol abuse or Positive in Urine drug screen test * Subject who determined that Investigator is unfit to participate in a clinical trial due to other reasons other than the above items
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peak Plasma Concentration (Cmax) | 0~48hours | PK Parameter |
| Area under the plasma concentration versus time curve of DA-8010 (AUClast) | 0~48hours | PK Parameter |
Countries
South Korea
Outcome results
None listed